A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication that the market for GLP-1 drugs could likely be a lot bigger. Based on data ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Dr. Darien Sutton and Dr. Stephanie Widmer discuss new studies, which found GLP-1 weight loss drugs beneficial in fighting ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Oluwafemi Adelakun has provided a detailed explanation of the numerous benefits of herbal medicine, highlighting its ...